Eupraxia Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPRX research report →
About the company
Eupraxia Pharmaceuticals Inc. , a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
- CEO
- James A. Helliwell
- IPO
- 2024
- Employees
- 49
- HQ
- Victoria, BC, CA
Price Chart
- Market Cap
- $223.98M
- P/E
- -6.39
- P/S
- 0.00
- P/B
- 2.76
- EV/EBITDA
- -4.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -50.81%
- ROIC
- -32.53%
- Revenue
- $0 · 0.00%
- Net Income
- $-53,858,075 · -111.33%
- EPS
- $-1.05 · -38.16%
- Op Income
- $-53,659,677
- FCF YoY
- 1.57%
- 52W High
- $9.32
- 52W Low
- $4.88
- 50D MA
- $6.83
- 200D MA
- $6.95
- Beta
- 1.50
- Avg Volume
- 286.63K
Get TickerSpark's AI analysis on EPRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our EPRX coverage
Recent articles, reports, and earnings notes.
No research on EPRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EPRX report →Similar companies
Peers in the same neighborhood.